COMMUNIQUÉS West-GlobeNewswire

Capricor Therapeutics Provides Regulatory Update on Deramiocel BLA Following FDA Review of HOPE-3 Topline Data
20/01/2026
FDA has requested the HOPE-3 clinical study report (CSR) as part of the BLA review process Company expects to submit updates to the BLA in February 2026 to support continued FDA review SAN DIEGO, Jan. 20, 2026 (GLOBE [...]
TOMI Environmental Solutions Secures UK CES contract integrating SteraMist iHP into Total Clean Air's Modular Cleanroom Platform
20/01/2026
FREDERICK, Md., Jan. 20, 2026 (GLOBE NEWSWIRE) -- TOMI Environmental Solutions, Inc. ® (“TOMI”) (NASDAQ: TOMZ), a global leader in disinfection and decontamination solutions, today announced the sale of a Custom [...]
Orphai Therapeutics’ Phase 2a LAM-001 Study Selected for Oral Presentation at the American Thoracic Society (ATS) 2026 International Conference
20/01/2026
NEW HAVEN, Conn., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Orphai Therapeutics Inc. (“Orphai”) , a clinical-stage biopharmaceutical company dedicated to advancing novel therapeutics for patients with diseases of significant [...]
Nasus Pharma Announces Positive Interim Results from Phase 2 Clinical Study of NS002 Intranasal Epinephrine Powder
20/01/2026
Interim results indicate NS002 demonstrated significantly faster absorption and higher peak epinephrine levels compared to EpiPen ® 91% of study participants achieved the 100 pg/ml plasma threshold at 5 minutes with [...]
Machina Medical Receives FDA 510(k) Clearance for MFUSE External Bleeding Control Device
20/01/2026
ROSWELL, Ga., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Machina Medical, Corp. today announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for MFUSE, a sterile, single-use medical device [...]
Spur Therapeutics Announces Platform and Poster Presentations Highlighting New Clinical Data for FLT201 in Gaucher Disease at Upcoming WORLDSymposium™
20/01/2026
LONDON, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Spur Therapeutics today announced that it will share updated clinical data from its Phase 1/2 GALILEO-1 and GALILEO-2 trials of avigbagene parvec (FLT201), its Phase 3 gene [...]
CorVel Corporation to Host Live Earnings Release Webcast
20/01/2026
FORT WORTH, Texas, Jan. 20, 2026 (GLOBE NEWSWIRE) -- CorVel Corporation (NASDAQ: CRVL), a leading provider of innovative risk management solutions, is pleased to announce that it will host a live webcast to discuss its [...]
FOXO Technologies Inc. Subsidiary, Big South Fork Medical Center, Expands Clinical Capabilities
20/01/2026
WEST PALM BEACH, FL, Jan. 20, 2026 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (“FOXO” or the “Company”) today announced that its critical access-designated acute care hospital, Scott County Community [...]
Aspect Biosystems and Novo Nordisk enter new phase of partnership to develop curative medicines for diabetes
20/01/2026
Partnership evolution includes strategic integration of select Novo Nordisk technologies into Aspect Biosystems Aspect will lead development, manufacturing and commercialisation, and Novo Nordisk will have defined [...]
Radix Health Rebrands as Pivotal Health
20/01/2026
Following rapid adoption of its Independent Dispute Resolution technology, Pivotal Health broadens its mission to help providers achieve fair reimbursement through technology NEW YORK, Jan. 20, 2026 (GLOBE NEWSWIRE) -- [...]
RenovoRx Expands RenovoCath® Commercial Adoption to Nine Active Cancer Centers Including City of Hope Cancer Center and Moffitt Cancer Center
20/01/2026
MOUNTAIN VIEW, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- RenovoRx, Inc. (“RenovoRx” or “the Company”) (Nasdaq: RNXT) , a life sciences company developing innovative targeted oncology therapies, today announced continued [...]
Quoin Pharmaceuticals Files Breakthrough Medicine Designation Application in Saudi Arabia for QRX003 in Netherton Syndrome
20/01/2026
If granted, QRX003 could be approved for sale and reimbursement in Saudi Arabia as a treatment for Netherton Syndrome in 2H 2026 QRX003 could become the first ever approved treatment for Netherton Syndrome ASHBURN, Va [...]
BrightInsight Announces Multi-Million Dollar Strategic Investment to Advance its AI-Enabled Medication Persistence and Adherence Solutions
20/01/2026
SAN JOSE, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- BrightInsight , a leader in digital health solutions, today announced a new investment round of $13 million from existing and new investors including Eclipse, General [...]
SPARK NS and Haukeland University Hospital Announce Clinical Trial of D-Serine for Modifying Parkinson’s Disease Progression
20/01/2026
Previous research indicates that D-Serine is safe, tolerable, and holds promise as a potential neuroprotective treatment for Parkinson’s MENLO PARK, Calif. and BERGEN, Norway, Jan. 20, 2026 (GLOBE NEWSWIRE) -- SPARK NS [...]
InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
20/01/2026
MIAMI, Jan. 20, 2026 (GLOBE NEWSWIRE) -- InspireMD, Inc. (Nasdaq: NSPR) (“InspireMD” or the “Company”), developer of the CGuard™ Prime carotid stent system for the prevention of stroke, today announced that the [...]
BioAge Announces Indication Expansion for Oral NLRP3 Inhibitor BGE-102, with Plans to Initiate Phase 1b/2a Proof-of-Concept Clinical Trial in Patients with Diabetic Macular Edema in Mid-2026
20/01/2026
BGE-102 has the potential for therapeutic retinal exposure with oral delivery, reducing treatment burden in ocular indications currently treated with intravitreal therapies Growing preclinical and clinical evidence [...]
New Imprivata Survey Finds 85% of Healthcare IT Leaders Think Passwordless Authentication is Vital, but Adoption Lags Significantly
20/01/2026
Just 7% of organizations have fully adopted passwordless authentication, citing technical integration challenges and clinical training concerns WALTHAM, Mass., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Imprivata , a leading [...]
Interpace Biosciences Announces Preliminary 2025 Revenue, 2026 Revenue Guidance and Simplification of Capital Structure
20/01/2026
Preliminary 2025 thyroid testing revenue grew 21% over prior year Initial 2026 guidance of 16% growth in thyroid testing revenue All preferred stock converted to common stock Debt-free balance sheet and positive Net [...]
Propanc Biopharma Files New Provisional Patent Application for Methods of Producing Trypsinogen & Chymotrypsinogen with IP Australia
20/01/2026
A World-First, Fully Synthetic Recombinant Version of PRP MELBOURNE, , Jan. 20, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on [...]

Pages